Chronic Kidney Disease Trial, Recruiting NCT07678073 Sponsor: University of Gaziantep Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT07678073
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 70 years of age who are in generally good to moderate overall health (as rated by a standard medical scale used by anaesthetists)
  • People scheduled for a planned kidney transplant where the kidney is coming from a living donor
  • People whose anaesthesia plan involves a specific inhaled anaesthetic medication called sevoflurane
  • People whose anaesthesia plan involves a combined spinal and epidural technique (a method of numbing the lower body using two types of injections in the back)

Who may not be able to join:

  • People younger than 18 or older than 70 years of age
  • People receiving a kidney from a deceased (non-living) donor
  • People whose anaesthesia plan involves all medications given through a drip rather than inhaled gas
  • People who do not wish to take part or are unable to give their own consent to join the study
  • People whose overall health is rated as very poor or critically ill on the standard anaesthetist health scale
  • People who have previously had an organ transplant of any kind
  • People with a known or suspected condition affecting how their cells produce energy (mitochondrial disorders)
  • People who have a history of long-term steroid medication use
  • People who need a red blood cell transfusion during the operation or within the first 24 hours after surgery
  • People where certain time limits related to how long the kidney was without full blood supply were exceeded during the transplant process (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Berna KAYA UĞUR, Doç. Dr., University of Gaziantep

Phone: +90 534 030 89 56

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Gaziantep
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
1 October 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Serum ferroptosis-related biomarkers (Fe, TFRC1, GPX4, MDA, ACSL4) and mitochondrial-derived peptides (humanin and MOTS-c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov